# MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT

> **NCT02931929** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medical University Innsbruck** · enrollment: 9 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** 68Ga-NeoBOMB1, 2-vial kit

## Key facts

- **NCT ID:** NCT02931929
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-04-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02931929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02931929, "MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02931929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*